Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Opinion Off Script TCT 2018

Off Script: Phantom Hearts and the Elusive Nature of Angina

Kwan S. Lee

October 11, 2018

Presentation TCT 2018

ABSORB Beyond 3 Years: ABSORB III 4-Year Data

Presenter: Bernard R. Chevalier, Stephen G. Ellis, Dean J. Kereiakes

September 22, 2018

Presentation TCT 2018

TCT-63: Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 24-month follow-up - BIOSOLVE-II and BIOSOLVE-III

Presenter: Antonio L. Bartorelli, David G. Rizik, Michael Haude

September 21, 2018

Presentation TCT 2018

TCT-61: Clinical Outcomes Following Complete Bioresorption of the Absorb Everolimus-Eluting Bioresorbable Scaffold: Four-year Results from the ABSORB III Trial

Presenter: Antonio L. Bartorelli, David G. Rizik, Dean J. Kereiakes

September 21, 2018

Podcast TCTMD Talking Points

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

August 22, 2018

News Industry News

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

May 24, 2018

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

News Industry News

Positive Five-Year Data Published for MiStent in EuroIntervention

January 12, 2018

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

Shelley Wood

January 01, 2018

Video

» Interview

TCT 2017: Dr. C. Michael Gibson talks with Dr. Stephen Ellis about ABSORB III

May 11, 2018

Advertisement

Off Script: Phantom Hearts and the Elusive Nature of Angina

ABSORB Beyond 3 Years: ABSORB III 4-Year Data

TCT-63: Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 24-month follow-up - BIOSOLVE-II and BIOSOLVE-III

TCT-61: Clinical Outcomes Following Complete Bioresorption of the Absorb Everolimus-Eluting Bioresorbable Scaffold: Four-year Results from the ABSORB III Trial

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Positive Five-Year Data Published for MiStent in EuroIntervention

The Biggest News of 2017: TCTMD’s Top 10

TCT 2017: Dr. C. Michael Gibson talks with Dr. Stephen Ellis about ABSORB III

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content